Administration costs of intravenous biologic drugs for rheumatoid arthritis.
about
Primary-care-based episodes of care and their costs in a three-month follow-up in FinlandAn estimate of the cost of administering intravenous biological agents in Spanish day hospitals.Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector.Managing Rheumatoid Arthritis with Dietary Interventions.Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.
P2860
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@en
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@nl
type
label
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@en
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@nl
prefLabel
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@en
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@nl
P2860
P356
P1433
P1476
Administration costs of intravenous biologic drugs for rheumatoid arthritis.
@en
P2093
Miina Leussu
Taru Hallinen
P2860
P2888
P356
10.1186/2193-1801-2-531
P50
P577
2013-10-17T00:00:00Z
P5875
P6179
1039556570